Neuracle, BrainCo and Arfysica line up for China's first BCI stock listings

Neuracle seeks about $345 million on Shanghai's STAR Market; BrainCo has filed in Hong Kong; none has priced yet.

Sep 14, 2026In briefIndustry Funding

Three Chinese brain-computer interface companies are in the queue to go public, though none has priced an offering yet:

Neuracle Medical, maker of the first commercially approved implanted BCI, filed for Shanghai’s STAR Market (prospectus accepted June 11) and is targeting about RMB 2.5 billion (US$345 million).
BrainCo, which makes non-invasive EEG headbands and bionic hands, filed confidentially in Hong Kong in January.
Arfysica Innovation, a rehabilitation-focused company, has only just begun preparing a STAR Market listing.

Public listings would give investors their first pure-play BCI stocks, following China’s push to commercialize the technology.

Sources

May 29, 2026FundingIndustry

Its FDA-cleared Quicktome maps each patient's brain networks; a new CPT code creates a US reimbursement route.

May 7, 2026FundingNeuromodulation

The company formerly known as MicroTransponder sells the only FDA-approved implant designed to improve arm function after chronic ischemic stroke.

Feb 11, 2026FundingIndustry

The Irish company's NEUROMARK system disables overactive nasal nerves using impedance-controlled radiofrequency energy.